MCID: INS002
MIFTS: 60

in Situ Carcinoma

Categories: Cancer diseases, Eye diseases, Gastrointestinal diseases, Oral diseases

Aliases & Classifications for in Situ Carcinoma

MalaCards integrated aliases for in Situ Carcinoma:

Name: in Situ Carcinoma 12 15
Carcinoma in Situ 45 74

Classifications:



External Ids:

Disease Ontology 12 DOID:8719
MeSH 45 D002278
NCIt 51 C2917
SNOMED-CT 69 68956006
ICD10 34 D09.9
UMLS 74 C0007099

Summaries for in Situ Carcinoma

Disease Ontology : 12 A carcinoma that is an early development defined by the absence of invasion of surrounding tissues.

MalaCards based summary : in Situ Carcinoma, also known as carcinoma in situ, is related to comedo carcinoma and lobular neoplasia. An important gene associated with in Situ Carcinoma is ESR1 (Estrogen Receptor 1), and among its related pathways/superpathways are GPCR Pathway and Circadian entrainment. The drugs Aluminum hydroxide and Epirubicin have been mentioned in the context of this disorder. Affiliated tissues include breast, cervix and testes, and related phenotypes are Decreased viability in esophageal squamous lineage and cellular

Wikipedia : 77 Carcinoma in situ (CIS) is a group of abnormal cells. While they are a form of neoplasm, there is... more...

Related Diseases for in Situ Carcinoma

Diseases in the Lip Cancer family:

Pre-Malignant Neoplasm Lip Carcinoma in Situ
in Situ Carcinoma Eye Carcinoma in Situ

Diseases related to in Situ Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 432)
# Related Disease Score Top Affiliating Genes
1 comedo carcinoma 33.7 ERBB2 ESR1
2 lobular neoplasia 33.4 BRCA1 CDH1 ERBB2 ESR1
3 endometrium carcinoma in situ 33.2 PGR TP53
4 cervix uteri carcinoma in situ 32.6 CDKN2A KRT17 TP53
5 ductal carcinoma in situ 32.0 BRCA1 BRCA2 CDH1 EGFR ERBB2 ESR1
6 vulva cancer 31.6 CDKN2A EGFR TP53
7 uterus carcinoma in situ 31.6 CDKN2A KRT17 TP53
8 cervical cancer 31.4 CDH1 CDKN2A ERBB2 KRT14 KRT5 TP53
9 breast carcinoma in situ 31.2 BRCA1 BRCA2 EGFR ERBB2 ESR1 KRT5
10 breast fibroadenoma 30.5 ERBB2 ESR1 KRT14 PGR
11 bladder cancer 30.3 CDH1 CDKN2A EGFR ERBB2 TP53
12 small cell carcinoma 30.3 CDKN2A EGFR TP53
13 breast ductal carcinoma 30.2 BRCA1 CDH1 EGFR ERBB2 ESR1 PGR
14 breast reconstruction 30.2 BRCA1 BRCA2
15 pleomorphic adenoma carcinoma 30.2 ERBB2 TP53
16 transitional cell carcinoma 30.1 CDH1 CDKN2A EGFR ERBB2 TP53
17 endometrial squamous cell carcinoma 30.1 CDKN2A ESR1 PGR
18 apocrine adenocarcinoma 30.0 ERBB2 ESR1 KRT5 PGR
19 carcinosarcoma 29.9 ERBB2 PGR TP53
20 intrahepatic cholangiocarcinoma 29.9 CDH1 EGFR TP53
21 actinic keratosis 29.9 CDKN2A KRT17 TP53
22 papillary carcinoma 29.9 CDH1 ERBB2 PGR
23 pleomorphic adenoma 29.8 ERBB2 KRT14 TP53
24 adenosquamous carcinoma 29.5 EGFR KRT5 TP53
25 mammary paget's disease 29.5 EGFR ERBB2 ESR1 PGR
26 microglandular adenosis 29.5 EGFR ERBB2 PGR TP53
27 gallbladder cancer 29.5 CDH1 CDKN2A EGFR ERBB2 TP53
28 vulva squamous cell carcinoma 29.5 CDKN2A KRT17 TP53
29 squamous cell carcinoma 29.4 CDH1 CDKN2A EGFR ERBB2 TP53
30 adenocarcinoma 29.4 CDH1 CDKN2A EGFR ERBB2 TP53
31 cholangiocarcinoma 29.4 CDH1 CDKN2A EGFR ERBB2 TP53
32 papilloma 29.3 CDKN2A KRT14 KRT5 TP53
33 esophageal cancer 29.1 CDH1 CDKN2A EGFR ERBB2 TP53
34 bilateral breast cancer 29.1 BRCA1 BRCA2 ERBB2 PGR
35 cervical squamous cell carcinoma 29.0 CDH1 CDKN2A TP53
36 ovarian cancer 1 29.0 BRCA1 BRCA2 CDH1 ERBB2 TP53
37 gastric adenocarcinoma 28.9 CDH1 CDKN2A EGFR ERBB2 TP53
38 fallopian tube carcinoma 28.7 BRCA1 BRCA2 ERBB2 ESR1 PGR TP53
39 female breast cancer 28.7 BRCA1 BRCA2 ERBB2 ESR1 PGR TP53
40 basaloid squamous cell carcinoma 28.7 CDKN2A EGFR KRT14 KRT17 TP53
41 lynch syndrome 28.5 BRCA1 BRCA2 CDKN2A EGFR TP53
42 ovarian cancer 28.5 BRCA1 BRCA2 CDH1 EGFR ERBB2 ESR1
43 breast disease 28.4 BRCA1 BRCA2 ERBB2 ESR1 KRT5 PGR
44 pancreatic cancer 28.4 BRCA1 BRCA2 CDH1 CDKN2A EGFR ERBB2
45 prostate cancer 28.2 BRCA1 BRCA2 CDH1 EGFR ERBB2 ESR1
46 endometrial cancer 27.9 BRCA1 BRCA2 CDH1 CDKN2A EGFR ERBB2
47 breast cancer 27.4 BRCA1 BRCA2 CDH1 EGFR ERBB2 ESR1
48 breast apocrine carcinoma in situ 12.5
49 oral cavity carcinoma in situ 11.7
50 nasal cavity carcinoma in situ 11.7

Graphical network of the top 20 diseases related to in Situ Carcinoma:



Diseases related to in Situ Carcinoma

Symptoms & Phenotypes for in Situ Carcinoma

GenomeRNAi Phenotypes related to in Situ Carcinoma according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability in esophageal squamous lineage GR00235-A 9.32 BRCA1 BRCA2 CDH1 CDKN2A ERBB2 ESR1

MGI Mouse Phenotypes related to in Situ Carcinoma:

47 (show all 25)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.51 BRCA1 BRCA2 CDH1 CDKN2A EGFR ERBB2
2 homeostasis/metabolism MP:0005376 10.48 AGTR1 BRCA1 BRCA2 CDH1 CDKN2A EGFR
3 growth/size/body region MP:0005378 10.47 AGTR1 BRCA1 BRCA2 CDH1 CDKN2A EGFR
4 mortality/aging MP:0010768 10.45 AGTR1 BRCA1 BRCA2 CDH1 CDKN2A EGFR
5 digestive/alimentary MP:0005381 10.44 BRCA1 BRCA2 CDH1 CDKN2A EGFR ERBB2
6 cardiovascular system MP:0005385 10.42 AGTR1 BRCA1 CDH1 CDKN2A EGFR ERBB2
7 endocrine/exocrine gland MP:0005379 10.42 BRCA1 BRCA2 CDH1 CDKN2A EGFR ERBB2
8 immune system MP:0005387 10.41 AGTR1 BRCA1 BRCA2 CDH1 CDKN2A EGFR
9 behavior/neurological MP:0005386 10.4 AGTR1 BRCA1 BRCA2 CDKN2A ERBB2 ESR1
10 integument MP:0010771 10.4 BRCA1 BRCA2 CDH1 CDKN2A EGFR ERBB2
11 hematopoietic system MP:0005397 10.37 AGTR1 BRCA1 BRCA2 CDKN2A EGFR ESR1
12 embryo MP:0005380 10.32 BRCA1 BRCA2 CDH1 CDKN2A EGFR ERBB2
13 adipose tissue MP:0005375 10.17 AGTR1 BRCA1 EGFR ESR1 KRT14 NR3C1
14 nervous system MP:0003631 10.17 AGTR1 BRCA1 BRCA2 CDKN2A EGFR ERBB2
15 neoplasm MP:0002006 10.16 BRCA1 BRCA2 CDH1 CDKN2A EGFR ERBB2
16 craniofacial MP:0005382 10.14 EGFR ERBB2 ITGB4 KRT14 KRT17 KRT5
17 limbs/digits/tail MP:0005371 10.11 BRCA1 BRCA2 EGFR ERBB2 ESR1 KRT5
18 muscle MP:0005369 10.08 BRCA1 CDKN2A EGFR ERBB2 ESR1 NR3C1
19 no phenotypic analysis MP:0003012 10.06 CDH1 CDKN2A EGFR ESR1 KRT17 KRT5
20 normal MP:0002873 10.02 BRCA1 BRCA2 CDH1 EGFR ERBB2 ESR1
21 reproductive system MP:0005389 9.93 BRCA1 BRCA2 CDH1 CDKN2A EGFR ERBB2
22 renal/urinary system MP:0005367 9.91 AGTR1 BRCA1 EGFR ESR1 FKBP4 ITGB4
23 pigmentation MP:0001186 9.8 BRCA1 CDKN2A EGFR KRT14 KRT17 TP53
24 respiratory system MP:0005388 9.61 BRCA1 CDKN2A EGFR ERBB2 ESR1 ITGB4
25 skeleton MP:0005390 9.28 BRCA1 BRCA2 CDKN2A EGFR ERBB2 ESR1

Drugs & Therapeutics for in Situ Carcinoma

Drugs for in Situ Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 425)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aluminum hydroxide Approved, Investigational Phase 4,Phase 3 21645-51-2
2
Epirubicin Approved Phase 4,Phase 3,Phase 2 56420-45-2 41867
3
Docetaxel Approved, Investigational Phase 4,Phase 3,Phase 2 114977-28-5 148124
4
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
5
Anastrozole Approved, Investigational Phase 4,Phase 3,Phase 2 120511-73-1 2187
6
Tamoxifen Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 10540-29-1 2733526
7
Sodium Citrate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 68-04-2
8
Bupivacaine Approved, Investigational Phase 4 38396-39-3, 2180-92-9 2474
9
Racepinephrine Approved Phase 4,Phase 3,Phase 2,Not Applicable 329-65-7 838
10
Epinephrine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 51-43-4 5816
11
Exemestane Approved, Investigational Phase 4,Phase 3,Phase 2 107868-30-4 60198
12
Letrozole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 112809-51-5 3902
13
Toremifene Approved, Investigational Phase 4,Phase 3,Phase 2 89778-26-7 3005573
14
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 77-92-9 311
15
Calcium Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7440-70-2 271
16 Vaccines Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
17 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
18 Monophosphoryl lipid A Phase 4
19 Anesthetics Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
20 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
21 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
22 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
23 Interferon-alpha Phase 4,Phase 3,Phase 1,Phase 2
24 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
25 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
26 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
27 interferons Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
28 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
29 Mitomycins Phase 4,Phase 3,Phase 2,Not Applicable
30 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
31 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1
32 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
33 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1
34 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
35 Selective Estrogen Receptor Modulators Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
36 Estrogen Receptor Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
37 Steroid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
38 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
39 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
40 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
41 Estrogens Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
42 Bone Density Conservation Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
43 Citrate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
44 Estrogen Receptor Modulators Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
45 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
46 Aromatase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
47 Estrogen Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
48 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Not Applicable
49 Epinephryl borate Phase 4,Phase 3,Phase 2,Not Applicable
50 Bronchodilator Agents Phase 4,Phase 2

Interventional clinical trials:

(show top 50) (show all 779)
# Name Status NCT ID Phase Drugs
1 FASTER-Tlalpan Study Unknown status NCT03105856 Phase 4
2 The Efficacy of Tachosil® for Prevention of Hemorrhage After Loop Electrosurgical Excisional Procedure (LEEP) Unknown status NCT02629510 Phase 4 Tachosil
3 Can Alternative Treatment Have an Impact on Cervical Dysplasia? Unknown status NCT00842738 Phase 4
4 Phase IV Trial to Evaluate Breast Brachytherapy Using the Mammosite-Ml® Completed NCT01448447 Phase 4
5 Electronic Xoft Intersociety Brachytherapy Trial: Electronic Brachytherapy (EBT) For Treatment of Early Stage Breast Cancer Completed NCT00742222 Phase 4
6 Photodynamic Therapy to Treat Actinic Damage in Patients With Squamous Cell Carcinoma (SCC) of the Lip Completed NCT00868088 Phase 4
7 Hemodynamic Stability of Bupivacaine With and Without Adrenaline for Paracervical Block for Cervical Conization Completed NCT02368054 Phase 4 Bupivacaine;Adrenaline
8 Topical Interferon Alfa 2b and Mitomycin C in Conjunctival-Corneal Intraepithelial Neoplasia Completed NCT02199327 Phase 4 Mitomycin C;Interferon Alfa-2b
9 HPV (Human Papilloma Virus) Vaccination After Treatment of Anal Intraepithelial Neoplasia (AIN) Completed NCT02087384 Phase 4 Placebo
10 Management of Cervical Intraepithelial Neoplasia Grade 2 Completed NCT00733109 Phase 4
11 V501 Safety and Efficacy Study in Japanese Women Aged 16 to 26 Years (V501-110) Completed NCT01544478 Phase 4
12 Immune Response to the Human Papillomavirus Vaccine in Young Women With Inflammatory Bowel Disease Completed NCT01034358 Phase 4
13 Neoadjuvant Chemotherapy With or Without Huaier Granule in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery Recruiting NCT02627248 Phase 4 Huaier Granule;Epirubicin;Docetaxel;Cyclophosphamide
14 HPV Vaccine Therapy in Interrupting Progression in Patients With High-Grade Vulvar or Anal Lesions Recruiting NCT03051516 Phase 4
15 Safety and Protective Effect Study of GSK Biologicals' Human Papillomavirus (Types 16, 18) Vaccine, Adsorbed (GSK580299) in Healthy Female Subjects From the HPV-039 Study Active, not recruiting NCT03629886 Phase 4
16 Effectiveness of Cervical Screening in HPV Vaccinated Women Enrolling by invitation NCT02149030 Phase 4
17 Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer Withdrawn NCT03238703 Phase 4 Anastrozole;Exemestane;Letrozole;Tamoxifen Citrate;Toremifene Citrate
18 Hyperthermia and Mitomycin C, Bacillus Calmette-Guerin, or Standard Therapy as Second-Line Therapy in Treating Patients With Recurrent Bladder Cancer Unknown status NCT01094964 Phase 3 epirubicin hydrochloride;mitomycin C
19 Topical Imiquimod for Bowen's Disease of the Head and Neck Unknown status NCT00384124 Phase 2, Phase 3 Imiquimod
20 Suction Drain Versus the Use of Adaptive Skin Sutures After Mastectomy ± Axillary Lymphadenectomy; a Prospective Randomised Study Unknown status NCT01509781 Phase 3
21 Spect Analysis of Cardiac Perfusion Changes After Whole Breast/Chest Wall Radiation Therapy With Active Breathing Coordinator Unknown status NCT00321048 Phase 3
22 Randomized Trial of Vaginal Self Sampling for Human Papillomavirus (HPV) Unknown status NCT01095198 Phase 2, Phase 3
23 Intravesical AD 32 (Valrubicin) in Patients With Carcinoma in Situ (CIS) of the Bladder Who Have Failed or Have Recurrence Following Treatment With Bacillus Calmette-guerin (BCG) Completed NCT01316874 Phase 2, Phase 3 Valrubicin, 800 mg
24 Evaluation of the Diagnostic Performance of MRI±Biopsy to Optimize Resection of Ductal Carcinoma In Situ (DCIS) Breast Cancer Completed NCT01112254 Phase 3
25 Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy Completed NCT00053898 Phase 3 anastrozole;tamoxifen citrate
26 Cystoscopy and Hexyl 5-Aminolevulinate in Detecting Carcinoma In Situ in Patients With Bladder Cancer Completed NCT00052637 Phase 3 hexaminolevulinate
27 Topical Imiquimod vs. LEEP for Women With Carcinoma In-situ of the Cervix Completed NCT02130323 Phase 2, Phase 3 Imiquimod
28 Genetic Counseling or Usual Care in Helping Women With Newly Diagnosed Ductal Carcinoma In Situ or Stage I, Stage II, or Stage IIIA Breast Cancer Make Treatment Decisions Completed NCT00262899 Phase 3
29 Mometasone Furoate in Preventing Radiation Dermatitis in Patients Undergoing Radiation Therapy to the Breast or Chest Wall for Invasive Breast Cancer or Ductal Carcinoma in Situ Completed NCT00438659 Phase 3 mometasone furoate
30 Intraoperative Gamma Camera for Breast Cancer Surgery Completed NCT00757302 Phase 3
31 Sequential Bacillus Calmette-Guérin (BCG) and Electromotive Mitomycin-C Versus Bacillus Calmette-Guérin (BCG) Alone for High Risk Superficial Bladder Cancer Completed NCT01442519 Phase 3 electromotive mitomycin
32 Hormone Replacement Therapy for Hot Flashes and/or Vaginal Symptoms in Postmenopausal Women Receiving Tamoxifen for Breast Cancer Completed NCT00026286 Phase 3 conjugated estrogens;medroxyprogesterone
33 Biological Therapy in Treating Patients With Bladder Cancer Completed NCT00003779 Phase 3
34 Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer Completed NCT00021255 Phase 3 Doxorubicin;Cyclophosphamide;Docetaxel;Herceptin;Carboplatin
35 Keyhole Limpet Hemocyanin Compared With Doxorubicin in Treating Patients With Bladder Cancer Completed NCT00006034 Phase 3 doxorubicin hydrochloride
36 Mycobacterial Cell Wall-DNA Complex in Treatment of BCG-refractory Patients With Non-muscle Invasive Bladder Cancer Completed NCT00406068 Phase 2, Phase 3 Mycobacterial cell wall-DNA complex
37 S9630, Medroxyprogesterone in Treating Women With Breast Cancer Completed NCT00002920 Phase 3 medroxyprogesterone;tamoxifen citrate
38 Study of Docetaxel in Breast Cancer Patients Completed NCT00174707 Phase 3 epidoxorubicine, ciclophosphamide, methotrexate, fluorouracile;epidoxorubicine, docetaxel, ciclophosphamide, methotrexate, fluorouracile;epidoxorubicine, docetaxel, cyclophosphamide
39 A Study of Blue Light Flexible Cystoscopy With Cysview in the Detection of Bladder Cancer in the Surveillance Setting Completed NCT02560584 Phase 3 Hexaminolevulinate hydrochloride
40 Surgery and BCG in Treating Patients With Bladder Cancer Completed NCT00002990 Phase 3
41 Docetaxel in Node Positive Adjuvant Breast Cancer Completed NCT00688740 Phase 3 Docetaxel;5-fluorouracil;Doxorubicin;Cyclophosphamide
42 Tykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo In Women With Early-Stage Breast Cancer Completed NCT00374322 Phase 3 lapatinib
43 Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer Completed NCT00038467 Phase 3 Tamoxifen;Exemestane
44 Simultaneous Study of Gemcitabine-Docetaxel Combination Adjuvant Treatment, as Well as Extended Bisphosphonate and Surveillance-Trial Completed NCT02181101 Phase 3 FEC-DocGemzar adjuvant chemotherapy;FEC-Doc adjuvant chemotherapy;Zoledronic acid i.v. 2 years;Zoledronic acid i.v. 5 years
45 Randomized Clinical Trial to Evaluate the Predictive Accuracy of a Gene Expression for Stage I-II Breast Cancer Completed NCT00336791 Phase 3 5-Fluorouracil;Cyclophosphamide;Doxorubicin;Paclitaxel;Epirubicin
46 Hormone Replacement Therapy and the Risk of Breast Cancer Recurrence in Women With Previous Early Stage Breast Cancer Completed NCT00003771 Phase 3 norethindrone acetate
47 A Follow-up Extension Study to Evaluate the Persistence of Immune Response to GSK Biologicals' HPV Vaccine in Healthy Chinese Female Subjects Who Received Three Doses of the Vaccine in the HPV-058 Study Completed NCT03355820 Phase 3
48 Randomized Clinical Trial on Clinical Management of ASCUS and LSIL (ALTS) Completed NCT01131312 Phase 3
49 Efficacy Study of Diathermy Cone Biopsy for the Treatment of Cervical Intraepithelial Lesion Completed NCT00995020 Phase 3
50 Human Papillomavirus (HPV) Vaccine Consistency and Non-inferiority Trial in Young Adult Women Completed NCT00337818 Phase 3

Search NIH Clinical Center for in Situ Carcinoma

Cochrane evidence based reviews: carcinoma in situ

Genetic Tests for in Situ Carcinoma

Anatomical Context for in Situ Carcinoma

MalaCards organs/tissues related to in Situ Carcinoma:

42
Breast, Cervix, Testes, Lymph Node, Prostate, Skin, Lung

Publications for in Situ Carcinoma

Articles related to in Situ Carcinoma:

(show top 50) (show all 3620)
# Title Authors Year
1
Occurrence of newly discovered human polyomaviruses in skin of liver transplant recipients and their relation with squamous cell carcinoma in situ and actinic keratosis - a single-center cohort study. ( 30632206 )
2019
2
Ameloblastic Carcinoma In Situ: Review of Literature and a Case Presentation in a Pediatric Patient. ( 29715060 )
2019
3
Concomitant carcinoma in situ may not be a prognostic factor for patients with bladder cancer following radical cystectomy: a PRISMA-compliant systematic review and meta-analysis. ( 30919100 )
2019
4
Long term oncologic outcome in patients with bladder cancer after radical cystectomy: Impact of carcinoma in situ in the era of neoadjuvant chemotherapy. ( 30706249 )
2019
5
Long-term Surveillance of Ductal Carcinoma in Situ Detected with Screening Mammography versus US: Factors Associated with Second Breast Cancer. ( 31038406 )
2019
6
Breast Ductal Carcinoma in Situ: Precursor to Invasive Breast Cancer. ( 31029232 )
2019
7
"Development and validation of algorithms to differentiate ductal carcinoma in situ from invasive breast cancer within administrative claims data" by Hirth JM, Hatch SS, Lin Y, Giordano SH, Silva HC, Kuo Y. ( 30875106 )
2019
8
PIK3CA mutations in ductal carcinoma in situ and adjacent invasive breast cancer. ( 30844755 )
2019
9
Influence of ductal carcinoma in situ on the outcome of invasive breast cancer. A prospective cohort study. ( 30738200 )
2019
10
Parity Differently Affects the Breast Cancer Specific Survival from Ductal Carcinoma In Situ to Invasive Cancer: A Registry-Based Retrospective Study from Korea. ( 30728717 )
2019
11
Growth Dynamics of Mammographic Calcifications: Differentiating Ductal Carcinoma in Situ from Benign Breast Disease. ( 31112087 )
2019
12
Functional Role of miRNAs in the Progression of Breast Ductal Carcinoma in Situ. ( 30273605 )
2019
13
Morphologic and Molecular Features of Breast Ductal Carcinoma in Situ. ( 30385094 )
2019
14
Legumain is an independent predictor for invasive recurrence in breast ductal carcinoma in situ. ( 30429518 )
2019
15
Molecular Evaluation of Breast Ductal Carcinoma in Situ with Oncotype DX DCIS. ( 30605628 )
2019
16
Sentinel lymph node biopsy in patients affected by breast ductal carcinoma in situ with and without microinvasion: Retrospective observational study. ( 30608397 )
2019
17
Association of Magnetic Resonance Imaging and a 12-Gene Expression Assay With Breast Ductal Carcinoma In Situ Treatment. ( 30653209 )
2019
18
MNK1/NODAL Signaling Promotes Invasive Progression of Breast Ductal Carcinoma In Situ. ( 30659022 )
2019
19
Identification of aberrant gene expression during breast ductal carcinoma in situ progression to invasive ductal carcinoma. ( 30712460 )
2019
20
The prognostic significance of lysosomal protective protein (cathepsin A) in breast ductal carcinoma in situ. ( 30725481 )
2019
21
miR-106b-5p and miR-17-5p could predict recurrence and progression in breast ductal carcinoma in situ based on the transforming growth factor-beta pathway. ( 30989460 )
2019
22
The clinical and biological significance of HER2 over-expression in breast ductal carcinoma in situ: a large study from a single institution. ( 31065110 )
2019
23
A retrospective alternative for active surveillance trials for ductal carcinoma in situ of the breast. ( 31018242 )
2019
24
Survival Outcomes for Women with Ductal Carcinoma in Situ in the Era of Supplemental Screening. ( 31039074 )
2019
25
Intraductal fulvestrant for Therapy of ERα-positive Ductal Carcinoma in Situ (DCIS) of the breast- a Preclinical Study. ( 31046118 )
2019
26
Frequency of pathogenic germline variants in BRCA1, BRCA2, PALB2, CHEK2 and TP53 in ductal carcinoma in situ diagnosed in women under the age of 50 years. ( 31060593 )
2019
27
Invasive ductal carcinoma with coexisting ductal carcinoma in situ (IDC/DCIS) versus pure invasive ductal carcinoma (IDC): a comparison of clinicopathological characteristics, molecular subtypes, and clinical outcomes. ( 31089799 )
2019
28
The Assisi Think Tank Meeting Survey of post-mastectomy radiation therapy in ductal carcinoma in situ: Suggestions for routine practice. ( 31092377 )
2019
29
Predictors of Invasive Breast Cancer in Patients With Ductal Carcinoma In Situ in Ultrasound-Guided Core Needle Biopsy. ( 30069893 )
2019
30
Risk stratification of ductal carcinoma in situ using whole-lesion histogram analysis of the apparent diffusion coefficient. ( 30073498 )
2019
31
Discordant HER2 immunohistochemical expression and gene amplification in ductal carcinoma in situ - evaluating HER2 in synchronous in-situ and invasive carcinoma. ( 30117181 )
2019
32
Accuracy of Breast Magnetic Resonance Imaging Compared to Mammography in the Preoperative Detection and Measurement of Pure Ductal Carcinoma In Situ: A Retrospective Analysis. ( 30149976 )
2019
33
Including the Ductal Carcinoma-In-Situ (DCIS) Score in the Development of a Multivariable Prediction Model for Recurrence After Excision of DCIS. ( 30190195 )
2019
34
Local Relapse After Breast-Conserving Therapy Versus Mastectomy for Extensive Pure Ductal Carcinoma In Situ ≥4 cm. ( 30253237 )
2019
35
Progression of ductal carcinoma in situ to invasive breast cancer: comparative genomic sequencing. ( 30284611 )
2019
36
Different Clinical and Pathologic Determinants Might be Possible to Predict Invasive Breast Cancer in Ductal Carcinoma In Situ in Ultrasound-Guided Core Needle Biopsy. ( 30298522 )
2019
37
Comparison of Clinical and Pathologic Characteristics of Ductal Carcinoma in Situ Detected on Mammography versus Ultrasound Only in Asymptomatic Patients. ( 30322671 )
2019
38
The decision to perform or omit sentinel lymph node biopsy during mastectomy for ductal carcinoma in situ should be tailored in accordance with preoperative findings. ( 30328007 )
2019
39
Evaluating the Rate of Upgrade to Invasive Breast Cancer and/or Ductal Carcinoma In Situ Following a Core Biopsy Diagnosis of Non-classic Lobular Carcinoma In Situ. ( 30362065 )
2019
40
Ductal Carcinoma in Situ Biomarkers in a Precision Medicine Era: Current and Future Molecular-Based Testing. ( 30385093 )
2019
41
Impact of pre-diagnosis depressive symptoms and health-related quality of life on treatment choice for ductal carcinoma in situ and stage I breast cancer in older women. ( 30406869 )
2019
42
In reply to Lambein et al.: 'HER2 protein overexpression in non-amplified ductal carcinoma in situ: quality issue or transcription mechanisms gone awry?' ( 30447011 )
2019
43
Stromal characteristics are adequate prognosticators for recurrence risk in ductal carcinoma in situ of the breast. ( 30454971 )
2019
44
Evaluating the frequency of upgrade to malignancy following surgical excision of high-risk breast lesions and ductal carcinoma in situ identified by core needle biopsy. ( 30461129 )
2019
45
Prognostic impact and possible pathogenesis of lymph node metastasis in ductal carcinoma in situ of the breast. ( 30474777 )
2019
46
HER2 protein overexpression in non-amplified ductal carcinoma in situ: quality issue or transcription mechanisms gone awry? ( 30480328 )
2019
47
Leveraging the variable natural history of ductal carcinoma in situ (DCIS) to select optimal therapy. ( 30536119 )
2019
48
Significant inter- and intra-laboratory variation in grading of ductal carcinoma in situ of the breast: a nationwide study of 4901 patients in the Netherlands. ( 30539380 )
2019
49
Breast conserving surgery with targeted intraoperative radiotherapy for the management of ductal carcinoma in situ. ( 30589080 )
2019
50
No Ink on Ductal Carcinoma In Situ: A Single Centre Experience. ( 30591495 )
2019

Variations for in Situ Carcinoma

Expression for in Situ Carcinoma

Search GEO for disease gene expression data for in Situ Carcinoma.

Pathways for in Situ Carcinoma

Pathways related to in Situ Carcinoma according to GeneCards Suite gene sharing:

(show all 30)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.64 BRCA1 BRCA2 CDKN2A EGFR ERBB2 ESR1
2
Show member pathways
12.89 EGFR ESR1 FKBP4 KRT14 KRT17 PGR
3
Show member pathways
12.75 BRCA2 CDH1 CDKN2A EGFR ERBB2 TP53
4 12.69 AGTR1 BRCA2 CDH1 CDKN2A EGFR ERBB2
5 12.38 BRCA1 CDKN2A EGFR ERBB2 TP53
6
Show member pathways
12.35 BRCA1 BRCA2 CDH1 CDKN2A EGFR ERBB2
7 12.19 EGFR ERBB2 ESR1 TP53
8
Show member pathways
12.15 AGTR1 EGFR ERBB2 PPP3R1
9
Show member pathways
12.11 EGFR ERBB2 ITGB4 TP53
10
Show member pathways
12.08 BRCA1 CDKN2A ESR1 NR3C1 PGR
11 12 EGFR ERBB2 ITGB4 TP53
12
Show member pathways
11.94 BRCA1 BRCA2 CDH1 CDKN2A EGFR ERBB2
13 11.92 BRCA1 BRCA2 CDH1 EGFR ESR1 TP53
14
Show member pathways
11.83 EGFR ERBB2 ESR1 PGR
15
Show member pathways
11.79 EGFR ERBB2 ESR1
16 11.78 BRCA1 EGFR FKBP4
17
Show member pathways
11.77 ESR1 NR3C1 PGR
18
Show member pathways
11.72 BRCA1 BRCA2 TP53
19 11.64 CDH1 EGFR ERBB2
20 11.62 BRCA1 CDKN2A ERBB2 TP53
21 11.59 BRCA1 ERBB2 TP53
22 11.58 EGFR ERBB2 TP53
23 11.58 CDH1 CDKN2A EGFR ERBB2 TP53
24 11.54 BRCA1 ERBB2 ITGB4
25 11.46 BRCA1 BRCA2 PPP3R1 TP53
26 11.42 CDKN2A EGFR TP53
27 11.35 FKBP4 KRT14 KRT17 KRT5 NR3C1 TP53
28 11.31 EGFR ERBB2 ITGB4 PPP3R1
29 11.2 CDH1 EGFR ERBB2 ITGB4
30 10.61 FKBP4 NR3C1

GO Terms for in Situ Carcinoma

Cellular components related to in Situ Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.89 BRCA1 BRCA2 CDH1 CDKN2A EGFR ERBB2
2 protein-containing complex GO:0032991 9.23 BRCA1 BRCA2 EGFR ESR1 FKBP4 NR3C1
3 cytosol GO:0005829 10 BRCA2 CDKN2A ERBB2 ESR1 FKBP4 KRT14

Biological processes related to in Situ Carcinoma according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 9.86 BRCA1 CDKN2A EGFR ESR1 NR3C1 PGR
2 regulation of apoptotic process GO:0042981 9.84 BRCA1 ESR1 PRDX2 TP53
3 positive regulation of transcription, DNA-templated GO:0045893 9.7 BRCA1 BRCA2 CDH1 CDKN2A EGFR ESR1
4 positive regulation of cell growth GO:0030307 9.69 EGFR ERBB2 KRT17
5 epidermis development GO:0008544 9.62 EGFR KRT14 KRT17 KRT5
6 replicative senescence GO:0090399 9.52 CDKN2A TP53
7 positive regulation of RNA polymerase II transcriptional preinitiation complex assembly GO:0045899 9.49 ESR1 TP53
8 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.48 EGFR TP53
9 negative regulation of ERBB signaling pathway GO:1901185 9.46 EGFR ERBB2
10 cellular response to indole-3-methanol GO:0071681 9.43 BRCA1 CDH1
11 negative regulation of immature T cell proliferation in thymus GO:0033088 9.4 CDKN2A ERBB2
12 chordate embryonic development GO:0043009 9.37 BRCA1 BRCA2
13 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.13 BRCA1 BRCA2 TP53
14 hemidesmosome assembly GO:0031581 8.8 ITGB4 KRT14 KRT5

Molecular functions related to in Situ Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase binding GO:0019901 9.8 CDKN2A EGFR ESR1 NR3C1 TP53
2 enzyme binding GO:0019899 9.72 BRCA1 EGFR ESR1 PGR TP53
3 protein phosphatase binding GO:0019903 9.63 EGFR ERBB2 TP53
4 protein binding GO:0005515 9.6 AGTR1 BRCA1 BRCA2 CDH1 CDKN2A EGFR
5 identical protein binding GO:0042802 9.56 BRCA1 BRCA2 CDH1 EGFR ERBB2 ESR1
6 steroid hormone receptor activity GO:0003707 9.54 ESR1 NR3C1 PGR
7 nitric-oxide synthase regulator activity GO:0030235 9.43 EGFR ESR1
8 nuclear receptor activity GO:0004879 9.43 ESR1 NR3C1 PGR
9 steroid binding GO:0005496 9.33 ESR1 NR3C1 PGR

Sources for in Situ Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....